Therefore, advantages of personalized approach in
treatment of bipolar disorder are being accentuated.
Guidelines recommendations are not being excluded
with this approach but are broadened to "softer"
segment of bipolar spectrum and new therapeutic goals
(neurocognitive deficiency, residual symptoms, suicidality).
For new therapeutic goals the treatment agents
are chosen based upon new understandings regarding
molecular foundation and psychosocial factors in
genesis and development of bipolar affective disorder